Activation of the PI3K downstream effector AKT pathway by NRG or EGF promotes lapatinib resistance in HER2+ breast cancer cells (Konecny et al., 2006; Weigelt et al., 2010; Wilson et al., 2012; Lovitt et al., 2015). The gene discussed is ERBB2; the disease is breast cancer.